Deals in Depth: August 2011
Merck is tasking Zymeworks' Azymetric platform for bi-specific cancer and autoimmune antibodies in a $187 million alliance. Par paid $410 million for generics company Anchen, while Baxter acquired additional medical delivery systems through its $380 million purchase of Baxa. With $334 million raised, device financing surpassed biopharma's $224 million in fundraising in August, thanks to large late-stage rounds from NeuroPace, Restoration Robotics and Entellus.
You may also be interested in...
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.